Merck Announces Results From New Phase III Study Amongst Women for Corifollitropin Alfa, an Investigational Fertility Treatment ...
SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the PURSUE Phase III study of 1,390 women, aged 35-42 years, for corifollitropin alfa, the company's investigational …